MA29810B1 - 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzènesulfonamides, procédés pour leur préparation et leur utilisation en tant que produits pharmaceutiques - Google Patents

4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzènesulfonamides, procédés pour leur préparation et leur utilisation en tant que produits pharmaceutiques

Info

Publication number
MA29810B1
MA29810B1 MA30788A MA30788A MA29810B1 MA 29810 B1 MA29810 B1 MA 29810B1 MA 30788 A MA30788 A MA 30788A MA 30788 A MA30788 A MA 30788A MA 29810 B1 MA29810 B1 MA 29810B1
Authority
MA
Morocco
Prior art keywords
thiadiazol
oxy
processes
preparation
benzenesulfonamides
Prior art date
Application number
MA30788A
Other languages
English (en)
Inventor
Stefanie Keil
Karl Schoenafinger
Matthias Urmann
Maike Glien
Wolfgang Wendler
Hans-Ludwig Schaefer
Eugen Falk
Hans Matter
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA29810B1 publication Critical patent/MA29810B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE LES 4-OXY-N-[1,3,4]-THIADIAZOL-2-YL-BENZÈNE SULFONAMIDES AINSI QUE LEURS SELS PHYSIOLOGIQUEMENT ACCEPTABLES ET LEURS DÉRIVÉS PHYSIOLOGIQUEMENT FONCTIONNELS PRÉSENTANT UNE ACTIVITÉ AGONISTE VIS-À-VIS DE PPARALPHA, PPARDELTA ET PPARGAMMA. L¿INVENTION CONCERNE DES COMPOSÉS DE FORMULE (I), LES RADICAUX ÉTANT TELS QUE DÉFINIS, AINSI QUE LEURS SELS PHYSIOLOGIQUEMENT ACCEPTABLES ET DES PROCÉDÉS POUR LEUR PRÉPARATION. LES COMPOSÉS CONVIENNENT POUR LE TRAITEMENT ET/OU LA PRÉVENTION DES PATHOLOGIES LIÉES AU MÉTABOLISME DES ACIDES GRAS ET À L¿UTILISATION DU GLUCOSE, AINSI QUE DES PATHOLOGIES LIÉES À LA RÉSISTANCE À L¿INSULINE ET À LA DÉMYÉLINISATION ET D¿AUTRES MALADIES NEURODÉGÉNÉRATIVES DU SYSTÈME NERVEUX CENTRAL ET PÉRIPHÉRIQUE.
MA30788A 2005-10-06 2008-03-31 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzènesulfonamides, procédés pour leur préparation et leur utilisation en tant que produits pharmaceutiques MA29810B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05021786 2005-10-06

Publications (1)

Publication Number Publication Date
MA29810B1 true MA29810B1 (fr) 2008-09-01

Family

ID=35455941

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30788A MA29810B1 (fr) 2005-10-06 2008-03-31 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzènesulfonamides, procédés pour leur préparation et leur utilisation en tant que produits pharmaceutiques

Country Status (15)

Country Link
US (1) US7910612B2 (fr)
EP (1) EP1937658A1 (fr)
JP (1) JP2009510144A (fr)
KR (1) KR20080053931A (fr)
CN (1) CN101277940A (fr)
AR (1) AR056121A1 (fr)
AU (1) AU2006299085A1 (fr)
CA (1) CA2624726A1 (fr)
IL (1) IL190460A0 (fr)
MA (1) MA29810B1 (fr)
NO (1) NO20081682L (fr)
RU (1) RU2008113210A (fr)
TW (1) TW200804324A (fr)
WO (1) WO2007039171A1 (fr)
ZA (1) ZA200801988B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2240474B1 (fr) 2007-12-26 2012-03-14 Sanofi Pyridyl-n-(1,3,4)-thiadiazol-2-yl-benzènesulfonamides cycliques, leurs procédés de préparation et leur utilisation comme produits pharmaceutiques
PE20120008A1 (es) * 2009-01-12 2012-01-24 Icagen Inc Derivados de fenoxi bencenosulfonamida
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
JP5872552B2 (ja) 2010-07-09 2016-03-01 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化学化合物
US9688673B2 (en) 2011-03-08 2017-06-27 The Regents Of The University Of California Deoxycytidine kinase binding compounds
HRP20250505T1 (hr) 2016-05-20 2025-06-20 Xenon Pharmaceuticals Inc. Spojevi benzensulfonamida i njihova uporaba za terapijska sredstva
WO2017202376A1 (fr) * 2016-05-26 2017-11-30 南京明德新药研发股份有限公司 Dérivé de sulfamide
ES2967410T3 (es) 2016-12-09 2024-04-30 Xenon Pharmaceuticals Inc Compuestos de bencenosulfonamida y sus usos en forma de agentes terapéuticos
AU2019216531A1 (en) 2018-02-02 2020-09-24 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
CN112262142B (zh) 2018-06-13 2023-11-14 泽农医药公司 苯磺酰胺化合物及其作为治疗剂的用途
MX2021001380A (es) 2018-08-31 2021-05-27 Xenon Pharmaceuticals Inc Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos.
MA53488A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
WO2022094409A1 (fr) 2020-11-02 2022-05-05 Trethera Corporation Formes cristallines d'un inhibiteur de la désoxycytidine kinase et leurs utilisations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS44204A (sr) * 2001-11-22 2007-06-04 Biovitrum Ab., Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1
WO2004103980A1 (fr) * 2003-05-21 2004-12-02 Biovitrum Ab Inhibiteurs de 11-beta-hydroxy steroide deshydrogenase de type i
US7173030B2 (en) * 2003-05-21 2007-02-06 Biovitrum Ab Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
EP1646628A1 (fr) * 2003-07-08 2006-04-19 Novartis AG Composes benzenesulfonylamino, et compositions pharmaceutiques contenant ces composes
CA2549385A1 (fr) * 2003-12-22 2005-07-21 Eli Lilly And Company Derive de triazole, oxadiazole et thiadiazole en tant que modulateurs de ppar pour le traitement du diabete

Also Published As

Publication number Publication date
AU2006299085A1 (en) 2007-04-12
CN101277940A (zh) 2008-10-01
KR20080053931A (ko) 2008-06-16
RU2008113210A (ru) 2009-10-10
NO20081682L (no) 2008-05-06
EP1937658A1 (fr) 2008-07-02
ZA200801988B (en) 2008-12-31
WO2007039171A1 (fr) 2007-04-12
JP2009510144A (ja) 2009-03-12
US7910612B2 (en) 2011-03-22
US20090012131A1 (en) 2009-01-08
TW200804324A (en) 2008-01-16
CA2624726A1 (fr) 2007-04-12
AR056121A1 (es) 2007-09-19
IL190460A0 (en) 2008-11-03

Similar Documents

Publication Publication Date Title
MA29810B1 (fr) 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzènesulfonamides, procédés pour leur préparation et leur utilisation en tant que produits pharmaceutiques
MA29804B1 (fr) Derives de phenyl-et pyridyl-1,2,4-oxadiazolone renfermant un groupe phenyle, procedes pour leur preparation et leur utilisation en tant qu'agents pharmaceutiques
Campolo et al. Multiple mechanisms of dimethyl fumarate in amyloid β‐induced neurotoxicity in human neuronal cells
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
MA30981B1 (fr) Derives de sulfonyl-phenyl-2h-(1,2,4)oxadiazol-5-one, procedes de preparation associes et utilisation comme medicaments
MA32323B1 (fr) Sulfonamides n-hétérocycliques annelés avec un groupe de tête oxadiazolone, procédés pour leur préparation et leur utilisation en tant qu'agents pharmaceutiques
MA30782B1 (fr) Amides substitues, procede de production et d'utilisation desdits amides
MA29805B1 (fr) Derives de phenyl-1.2.4-oxadiazolone, leurs procedes de preparation et leur utilisation comme produits pharmaceutiques
TN2009000138A1 (fr) Biaryl-ether-urees
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
MA35874B1 (fr) Dérivés d'amide cycliques à utiliser en tant qu'inhibiteurs de 11-bêta-hydroxystéroïde déshydrogénase et utilisations de ceux-ci
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
MA30084B1 (fr) Triazolopyridazines en tant que modulateurs de la tyrosine kinase
MA47447B1 (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA33450B1 (fr) Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques
IL167694A (en) Use of quinazulin-4-on derivatives is used to make derivatives and pharmaceutical preparations containing the derivatives
MA27097A1 (fr) Aza-arylpiperazines
MA29812B1 (fr) N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides cycliques, procedes pour leur preparation et leur utilisation en tant que substances pharmaceutiques
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MA30916B1 (fr) Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine
MA32120B1 (fr) Nouveaux composes chimiques
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA29379B1 (fr) Derives de pyrrolidine 3,4-substitues pour le traitement de l'hypertension
MA31857B1 (fr) N-phenyl-pyrrolidinylmethylpyrrolidine-amides substitues et utilisation therapeutique de ceux -ci
MA29723B1 (fr) Composes